What do biotech companies actually do during the YC 3-month program?

During the 3-month program, biotech companies focus on refining their go-to-market strategy and planning essential steps for funding. They might conduct critical path experiments, work with regulatory consultants, and engage with potential customers to minimize noise and maximize focus.

Do biotech founders usually need a business co-founder?

No, scientists are often well-equipped with necessary business skills like articulation and strategy from their academic work. The focus for biotech is typically on technological risk and de-risking the innovation, rather than market uncertainty common in software companies.

What is 'de-risking' in the context of biotech innovation?

De-risking in biotech involves gathering experimental data to prove a therapeutic intervention's efficacy. This includes showing results in animal or cell models, developing the therapeutic, conducting toxicity studies, and obtaining initial proof-of-concept data before human trials.

What's the typical stage of biotech companies applying to YC?

Companies often apply to YC when they have initial data suggesting a promising approach to treating or testing a disease. They are typically at the discovery stage, bridging the gap between initial experimental data and early proof-of-concept in the clinic, an area with significant underinvestment.

How important is intellectual property (IP) for biotech companies?

IP is fundamental to biotech strategy because it underpins the massive investment required for development and provides a necessary window of exclusivity for market recovery. Without IP protection, developing drugs would be financially unsustainable.

What is the fundraising path for biotech companies after YC?

Post-YC biotech companies often raise significant seed rounds from Silicon Valley funds that are increasingly interested in science. These funds include traditional VCs like Khosla Ventures, Founders Fund, and NEA, demonstrating a growing appetite for biotech innovation beyond software.

What are the current exciting advancements in biotech research?

Exciting areas include the application of AI in predicting efficacy and toxicity, novel clinical study designs for faster initial human data, and gene editing tools like CRISPR. CRISPR is considered game-changing for its potential in editing genetic defects and high-throughput screens.

Is there real science behind life extension claims, or is it mostly hype?

Life extension research faces challenges due to the lack of reliable human endpoints. While research like calorie restriction and parabiosis shows promise in model systems, translation to humans is difficult. Currently, many claims may be considered 'hype' or 'snake oil' until more robust clinical data emerges.

Key Moments

Elizabeth Iorns on Biotech Companies in YC

Y Combinator

Science & Technology6 min read41 min video

Sep 13, 2017|5,295 views|72|1

YC Y Combinator Podcast Interview Elizabeth Iorns Biotech

Save to Pod

Key Moments

On this page

TL;DR

YC helps biotech startups by connecting them to capital, diverse tech insights, and de-risking their innovations.

Key Insights

Y Combinator (YC) offers biotech startups access to capital, expertise in fundraising, and exposure to diverse cutting-edge technologies.

The three-month YC program focuses biotech companies on defining their minimum viable product and go-to-market strategy, rather than fundamental scientific breakthroughs.

Biotech companies in YC can utilize their funds for critical path experiments (often outsourced), regulatory consulting, and customer validation.

Founders in biotech typically learn business and market strategy during YC rather than needing a pre-existing business co-founder, as scientists possess necessary communication and strategic skills.

De-risking technology in biotech involves generating experimental data, such as proof-of-concept in animal or cell models, and toxicity studies.

The funding gap YC addresses for biotechs is translating academic discovery into initial proof-of-concept data relatable to the clinic.

The 'postdoc epidemic' drives many PhDs and postdocs to consider entrepreneurship as an alternative career path.

Intellectual property (IP) is crucial in biotech for recouping significant development investments, and YC assists with licensing strategies.

Biotech companies are increasingly raising significant seed funding from Silicon Valley and other tech-focused investors.

The biotech funding landscape includes traditional venture capital models and a growing opportunity for academic discoverers to found companies.

Education on entrepreneurial basics, like understanding investment vs. payback, is vital for scientists transitioning to startups.

Emerging areas of interest in biotech include AI in drug development, optimized clinical study design, CRISPR technology applications, and longevity research.

Longevity research faces challenges with defining clear human endpoints, making progress like calorie restriction and parabiosis research complex to validate.

Fasting and personalized responses to food are areas of personal interest and ongoing research in health and wellness.

UNDERSTANDING Y COMBINATOR'S ROLE FOR BIOTECH

Elizabeth Iorns, CEO of Science Exchange and a YC partner, explains that Y Combinator (YC) offers unique benefits to biotech startups. For those unfamiliar with YC, it provides foundational support for company launch, focusing on product-market fit and growth. For more established biotech professionals, YC offers significant access to capital, fundraising expertise, and exposure to diverse, cutting-edge technologies like AI, which can lead to unexpected collaborations and funding opportunities. Many biotech companies have raised substantially more capital through YC than they might have in traditional venture capital routes, with over $200 million already raised by YC biotech companies.

THE THREE-MONTH YC JOURNEY: FOCUS AND STRATEGY

The three-month YC program may not facilitate fundamental scientific breakthroughs, but it provides a crucial focus for biotech companies. The core objective is to identify the minimal viable product and hone the go-to-market strategy, enabling efficient execution. While experimental work may continue, the primary advancement is in market understanding and charting a clear path toward securing funding for future development. This focused approach helps minimize distractions and directs energy toward critical business and strategic milestones, which is a significant achievement within the compressed timeframe.

ALLOCATING RESOURCES AND DE-RISKING INNOVATION

During the YC program, biotech companies strategically use their limited funds for critical path experiments, often by outsourcing them to external service providers for quick results. They also engage regulatory consultants to refine their go-to-market strategies and advance filing statuses. A significant portion of the effort is dedicated to de-risking the technology, which involves generating experimental proof points like therapeutic efficacy in animal or cell models, or conducting toxicity studies necessary for initial human trials. Customer discovery and market validation are also key activities.

SCIENTISTS AS ENTREPRENEURS: MARKET AND CO-FOUNDERS

Unlike software startups, biotech companies often face less uncertainty about market size; the primary challenge is technological risk. YC focuses on de-risking this innovation by generating robust experimental data. The notion that scientists are antisocial or lack business acumen is a misconception. Scientists are typically articulate, experienced in presenting to large audiences, and skilled in grant writing, making them well-equipped to lead. Therefore, the need for a dedicated business co-founder from the outset is often minimal, as these skills can be developed during the YC program.

THE 'POSTDOC EPIDEMIC' AND THE TRANSLATIONAL GAP

A significant driver for scientists considering entrepreneurship is the 'postdoc epidemic,' where limited academic positions leave many highly trained PhDs and postdocs seeking alternative career paths. YC aims to bridge the 'translational gap' between academic discoveries and clinical application. While academia offers initial research funding, there's a substantial challenge and investment gap in translating these findings into viable products. YC helps companies that have initial promising data but need to move towards clinical proof-of-concept, an area often underfunded by traditional investors focused on later-stage developments.

INTELLECTUAL PROPERTY AND LICENSING IN BIOTECH

Intellectual property (IP) is the cornerstone of biotech strategy, essential for recouping massive development costs and securing market exclusivity. In academic settings, IP is typically owned by the university, requiring a licensing process through tech transfer offices. YC assists biotech companies in navigating these licensing complexities, helping them build a compelling case to secure the necessary IP rights. This process is critical for enabling investment and eventual commercialization of groundbreaking discoveries made during academic research.

FUNDRAISING POST-YC AND INVESTMENT TRENDS

Following the YC program, biotech companies often attract significant seed funding, with many raising several million dollars. The trend shows strong appetite from early-stage technology investors and specialized VCs, even those not traditionally focused on biotech, indicating a convergence of tech and life sciences. Funds like Khosla Ventures and Founders Fund are actively investing. While historical data is still accumulating, companies are successfully progressing to Series A rounds, demonstrating the viability of the YC pathway for sustained growth and future institutional investment.

TRADITIONAL BIOTECH FUNDING VS. ACADEMIC INNOVATION

Historically, biotech funding has often favored repeat entrepreneurs or internal incubation strategies within large venture funds that license discoveries and build teams. However, there's a growing recognition of the value of supporting academic discoverers as founders. YC provides a pathway for these individuals, offering mentorship and funding to help them navigate the steep learning curve of drug development and regulatory processes. This approach aims to increase diversity in biotech innovation and bring more unique discoveries to market.

EDUCATING SCIENTISTS ON ENTREPRENEURSHIP

A significant hurdle for scientists is a lack of foundational understanding of entrepreneurship, including concepts like investment versus payback. YC addresses this by providing education and a framework for company formation, reducing misconceptions and fear. The program instills confidence in the process, clarifying that investment capital does not need to be repaid personally if the company fails. This educational aspect is crucial for empowering scientists to explore entrepreneurial paths with less apprehension, especially given the career uncertainties within academia.

CUTTING-EDGE DEVELOPMENTS AND EMERGING TECHNOLOGIES

Iorns highlights several exciting areas at the forefront of biotech innovation. The application of Artificial Intelligence (AI) in predicting drug efficacy and toxicity, and in optimizing clinical study designs for faster results, is a key focus. CRISPR technology is seen as game-changing, enabling precise gene editing, though its therapeutic applications are still under rigorous testing. There's also innovation in transient gene expression editing, which may face fewer regulatory hurdles than direct DNA modification.

THE COMPLEXITY OF LONGEVITY RESEARCH

Longevity and life extension research, while popular, presents significant scientific challenges, particularly in establishing measurable human endpoints. Unlike cancer research, where tumor size or survival rates offer clear metrics, aging research lacks easily quantifiable outcomes. Models like C. elegans are used, but translating findings to humans is difficult. Research into calorie restriction shows mixed results across different models, and the mechanisms behind parabiosis (connecting young and old blood) are still debated, indicating that much of this field is still in its early, exploratory stages.

PERSONAL HEALTH HABITS AND FUTURE RESEARCH INTERESTS

Elizabeth Iorns practices intermittent fasting, finding it beneficial for appetite control despite some cognitive fogginess during the fast. She notes the scientific basis for fasting's metabolic benefits. Her future research interests lie in personalized nutrition, exploring why individuals respond differently to diets. Current research in this area involves monitoring glucose and insulin responses to food, suggesting a move towards highly individualized dietary recommendations based on biological reactions rather than generalized advice.

Mentioned in This Episode

●Software & Apps

●Companies

●Organizations

●Books

●Concepts

●People Referenced

Biotech Fundraising Landscape

Data extracted from this episode

Entity	Investment Focus
Khosla Ventures	Biotech and Science Companies
Jason Horowitz-led funds	Biotech and Science Companies
Data Collective	Science and Technology Companies
Founders Fund	Science and Technology Companies
NEA	Companies combining software insights with biological world
Third Rock	Internal incubation strategy for biotech
Atlas Venture	Internal incubation strategy for biotech
Polaris Partners	Internal incubation strategy for biotech
Flagship Pioneering	Internal incubation strategy for biotech

Common Questions

Biotech companies can benefit from Y Combinator's access to capital, fundraising expertise, and exposure to diverse, cutting-edge technologies like AI. It helps hone their go-to-market strategy efficiently and can lead to significantly more capital raised than traditional biotech venture routes.

Topics

Health & Longevity Technology & Innovation Science & Mathematics Venture Capital Gene Editing Startup Funding Drug Development Personalized Medicine Academic Research Longevity Research Biotech Startups

Mentioned in this video

People

Elizabeth Iorns

Founder and CEO of Science Exchange, former cancer biologist, and part-time partner (expert program) at Y Combinator focusing on biotech companies.

Jason Horowitz

Associated with leading investments in the biotech and science space.

Organizations

Nature

A prominent scientific journal publishing cutting-edge biological research.

Science (journal)

A scientific journal where cutting-edge research, particularly in cancer biology, is published.

Cell

A scientific journal that publishes significant research in life sciences, including those relevant to YC biotech applications.

Institute of Cancer Research

The institution where Elizabeth Iorns completed her PhD.

University of Miami

The university where Elizabeth Iorns completed her postdoc and later became an assistant professor.

NEA

A venture capital firm interested in science and biotech companies, particularly those combining software insights with biology.

Concepts

CRISPR

A revolutionary gene-editing technology that is game-changing and allows for previously unimaginable biological manipulations, with significant potential in therapeutic applications and high-throughput screens.

Telomeres

A potential endpoint for measuring aging and longevity, though its reliability is questioned due to 'noise' and difficulty in establishing effectiveness in humans.

Fasting

Elizabeth Iorns attempts to practice fasting monthly for its potential benefits on metabolic control and appetite, though she finds it difficult to sustain, especially on workdays.

C. Elegans

A model organism (nematode worm) used in research to study aging and longevity, although its results may not always translate directly to humans.

Parabiosis

A trend in life extension research involving connecting the bloodstreams of young and old animals to study the effects of factors in young blood, but the specific active component remains controversial and unreproducible.

Software & Apps

RNAi screens

A technology used for inhibiting gene expression, which laid groundwork for CRISPR applications, although prone to errors and transient effects.

Companies

Science Exchange

A company founded by Elizabeth Iorns in 2011, which facilitates outsourcing of R&D for pharmaceutical companies and works with early-stage biotech companies.

Khosla Ventures

A venture capital firm that actively invests in biotech and science companies.

Founders Fund

A venture capital firm that invests in science and technology companies.

Y Combinator

A startup accelerator that Elizabeth Iorns's company, Science Exchange, was part of in the 2011 summer batch. She now serves as a part-time partner focusing on biotech companies applying to YC.

Data Collective

A venture capital firm that invests in science and technology companies.

Atlas Venture

A venture capital firm that employs an internal incubation strategy for developing biotech companies.

Polaris Partners

A venture capital firm known for its successful internal incubation strategy in the biotech sector.

Flagship Pioneering

A venture capital firm that utilizes an internal incubation strategy to build and fund biotech companies.

condition

Alzheimer's disease

Mentioned as an example of a disease where a biotech company might aim to develop a therapeutic intervention.